Expect up to 130 companies to list in Hong Kong this year: KPMG
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma' or the 'Company'), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company's Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company's Chairman & Chief Executive Officer. Dr. Yang said, 'I am excited to welcome Veet and Eric to our senior management team. As an innovative biopharmaceutical company dual listed on the Hong Kong Stock Exchange and Nasdaq, Ascentage Pharma is entering a phase of notable growth. The addition of these seasoned executives will help accelerate the implementation of our global strategy of becoming a leading, fully integrated global biopharmaceutical company.' Dr. Misra brings a rare combination of deep scientific background in biology and significant experience in U.S. capital markets in the biopharmaceutical sector. 'I am confident that Veet's unique blend of scientific acumen and capital markets expertise can help us garner stronger traction in the global capital markets and strengthen our operations,' added Dr. Yang. Mr. Huang brings rich expertise in the global pharmaceutical industry and a wealth of experience in corporate management. 'This makes Eric a great match for Ascentage Pharma's long-term growth needs. His experience will help drive excellence in Ascentage Pharma's corporate operations as the Company continues to make headway in expanding globally,' said Dr. Yang. Dr. Misra commented, 'I am thrilled to join Ascentage Pharma as its Chief Financial Officer. Ascentage Pharma is a global leader in apoptosis-targeted therapies. Its dual listing in Hong Kong and the U.S. reflects strong recognition of the Company in these two premier markets. I look forward to working with my colleagues to accelerate the global development of the Company's innovative pipeline and create sustained value for patients and shareholders.' Mr. Huang said, 'It is my great honor to join Ascentage Pharma, a company that has established growing global competitiveness in the field of hematologic malignancies. The strategic partnership with Takeda and the dual listing in Hong Kong and the U.S. have created a sound foundation for global expansion. I look forward to working closely with the Company's management team to further improve operations and efficiently integrate the Company's existing resources to accelerate the global development and commercialization of its core assets, ultimately bringing more novel therapeutics to patients in need.' Dr. Misra has more than 20 years of experience in investment banking. Prior to joining Ascentage Pharma, he was a Managing Director in the Healthcare Investment Banking group at Cantor Fitzgerald where he covered the biopharmaceutical sector. Before that, he worked in the life sciences investment banking groups at Houlihan Lokey and RBC Capital Markets. Over the course of his banking career, Dr. Misra advised on deals spanning equity, equity-linked, debt, and debt restructuring, as well as buy-side/sell-side M&A and corporate strategy, primarily focusing on the biotechnology sector. Dr. Misra earned a Ph.D. in Molecular Biology, with a focus on the oncology field, from the University of Toronto and an MBA in Finance & Strategy from the Schulich School of Business in Toronto. Mr. Huang has served in various managerial positions at multinational companies for more than 20 years and possesses extensive experience in driving continuous financial performance improvement, business/operational excellence, and global operations. Prior to joining Ascentage Pharma, Mr. Huang served as the Chief Financial Officer for Greater China and Asia-Pacific at Beigene, where he also led Global Technical Operations Finance and Global Commercial Finance, and implemented comprehensive financial planning management and optimized globally-based resource allocation leading to sustained financial improvements. Before that, Mr. Huang was at Novartis, where he served as the head of finance for multiple countries and regions. Mr. Huang received an MBA in Finance from Dowling Business School. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ContactsInvestor Relations:Hogan Wan, Head of IR and StrategyAscentage 512 85557777 Stephanie CarringtonICR (646) 277-1282 Media Relations:Sean LeousICR (646) 866-4012
Yahoo
41 minutes ago
- Yahoo
Nvidia stock: Why investors are bullish again
Nvidia (NVDA) stock has rebounded from April lows as investor concerns around tariffs, China, and artificial intelligence (AI) capital expenditure (CapEx) risks have eased. Patrick Moorhead, founder, CEO, and chief analyst at Moor Insights & Strategy, joins Market Domination Overtime to explain why optimism around industrial and enterprise AI is keeping demand and spending alive. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Let's begin with Nvidia. Big run off the April low. A name a lot of people know. A name a lot of people watching right now, certainly own. What explains that move off the April low? Yeah, so a lot of risks were taken down, you know, it was screaming for so long and then tariffs hit, uh, China hit, uh, potential GDP concerns, even questions about capex. And nearly all of them just completely evaporated and came off the table. So the risk is lower in the perception with investors. And for the first time, this year, this year of the potential next wave of Industrial AI, investors are starting to see the correlation, the potential upside. You mentioned capex, which is an interesting point because there were some skeptics we had on the show who were arguing perhaps that maybe 2025 is going to represent some sort of high mark, some sort of peak in AI capex, and that was bad news for the likes of Nvidia. Do you buy that? Uh, I don't, but I do think the growth will be tempered, right? Well, we see 10% growth, 20% growth likely. We won't be seeing 50% growth. But the other, the only thing that could change my mind on that is I'm doing a little bit more research on the industrial edge and also enterprise AI because as AI gets permeated into everything, into businesses, on premises, and even in the industrial edge, somebody is going to have to pay for that equipment. And if it's not going to be who you might expect, let's say the carriers, uh, the folks who are out there investing in it today, other companies might have to come in, let's say the hyperscalers go after that.
Yahoo
an hour ago
- Yahoo
Asian Penny Stocks To Watch With Market Caps At Least US$200M
As global markets continue to navigate a complex landscape, Asian stocks remain a focal point for investors seeking opportunities in diverse economies. Penny stocks, often overlooked due to their vintage nomenclature, still represent an intriguing segment for those interested in smaller or newer companies. By focusing on financial robustness and growth potential, these stocks can offer unexpected value and stability amidst broader market movements. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.28 HK$807.62M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$2.09 HK$3.61B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.22 HK$1.85B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.42 SGD170.22M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.11 HK$1.85B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.38 THB2.63B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.19 SGD8.62B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.21 SGD42.46M ★★★★★★ BRC Asia (SGX:BEC) SGD3.17 SGD869.69M ★★★★★★ United Energy Group (SEHK:467) HK$0.52 HK$13.44B ★★★★★★ Click here to see the full list of 991 stocks from our Asian Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Inkeverse Group Limited is an investment holding company that operates mobile live streaming platforms in the People's Republic of China, with a market cap of HK$2.56 billion. Operations: The company generates revenue primarily from its Live Streaming Business, which amounted to CN¥6.85 billion. Market Cap: HK$2.56B Inkeverse Group, with a market cap of HK$2.56 billion, primarily generates revenue from its Live Streaming Business amounting to CN¥6.85 billion. Despite being debt-free and having strong short-term assets (CN¥4 billion) exceeding liabilities, the company faces challenges with negative earnings growth (-53.4%) and reduced profit margins (2.6% from 5.6%). A significant one-off loss of CN¥99.7 million impacted recent financials, highlighting volatility in performance despite stable weekly volatility at 8%. The experienced board and management team offer some stability as the company trades below estimated fair value by 24.2%. Click here and access our complete financial health analysis report to understand the dynamics of Inkeverse Group. Evaluate Inkeverse Group's historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Low Keng Huat (Singapore) Limited is an investment holding company involved in property development, hotel operations, and investments across Singapore, Australia, and Malaysia with a market cap of SGD280.75 million. Operations: The company's revenue is primarily derived from property development at SGD415.78 million, supplemented by hotel operations generating SGD50.08 million and investments, including construction, contributing SGD66.71 million. Market Cap: SGD280.75M Low Keng Huat (Singapore) Limited, with a market cap of SGD280.75 million, derives significant revenue from property development (SGD415.78 million), hotel operations (SGD50.08 million), and investments including construction (SGD66.71 million). The company recently became profitable, although earnings have declined by 50.5% annually over the past five years. Short-term assets of SGD409 million comfortably cover both short and long-term liabilities, yet the net debt to equity ratio remains high at 62.1%. Despite stable weekly volatility at 6%, interest coverage is weak at 1.3x EBIT, and dividend payments are not well supported by earnings. Get an in-depth perspective on Low Keng Huat (Singapore)'s performance by reading our balance sheet health report here. Gain insights into Low Keng Huat (Singapore)'s historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Xiamen Hexing Packaging Printing Co., Ltd. operates in the packaging and printing industry, with a market cap of CN¥4.19 billion. Operations: The company generates revenue of CN¥11.23 billion from its packaging manufacturing industry segment. Market Cap: CN¥4.19B Xiamen Hexing Packaging Printing Co., Ltd. demonstrates a stable financial position with short-term assets of CN¥4.4 billion exceeding both its short and long-term liabilities, reflecting solid liquidity. The company's net debt to equity ratio at 16.6% is satisfactory, and its interest payments are well covered by EBIT at 3.5x coverage, indicating manageable leverage levels. While earnings growth over the past year outpaced the industry average, profitability remains modest with a net profit margin of 1%. Recent activities include a share buyback program worth up to CN¥100 million and a cash dividend increase, suggesting shareholder-friendly initiatives despite fluctuating revenue figures. Take a closer look at Xiamen Hexing Packaging Printing's potential here in our financial health report. Examine Xiamen Hexing Packaging Printing's earnings growth report to understand how analysts expect it to perform. Discover the full array of 991 Asian Penny Stocks right here. Ready For A Different Approach? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3700 SGX:F1E and SZSE:002228. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
